Research perspective
The antigen’s location changes the recognition question
Mutant KRAS is an intracellular tumor-associated driver. Conventional CAR recognition is directed to an accessible surface target. TCR recognition instead depends on a particular antigenic peptide associated with HLA. These mechanisms can be studied alongside one another, but one should not be treated as evidence for the other.
For research that uses an APC, the first task is to establish the intended peptide–HLA target. An antigen construct may be expressed while the relevant epitope remains poorly processed, infrequently presented or unrecognized by the available T cells. Antigen expression is therefore one measurement in a chain of evidence.
What published evidence establishes
Tran and colleagues reported a colorectal cancer case in which KRAS G12D-reactive T cells mediated tumor regression. Recognition depended on HLA-C*08:02, and a progressing lesion lost that allele. Read the primary report ›
This patient-specific finding motivates antigen/HLA research and an explicit examination of escape. It does not validate presentation on HLA-A*02:01 or recognition of another KRAS variant. Each proposed antigen/HLA pairing requires its own evidence.
Pancreatic cancer vaccine studies also motivate questions about response persistence. A 2025 phase 1 follow-up reported durable functional neoantigen-specific responses in vaccine responders, with recurrence associations that require interpretation in the small, combined-treatment setting. Read the follow-up study ›
Turn a program concept into testable research questions
Antigen-directed priming, response breadth and repeated APC support can be investigated together. Each requires a defined experimental comparison; the proposed combination remains a research question.
| Research question | Evidence needed |
|---|---|
| Is the intended peptide presented? | Confirm HLA context and seek direct peptide–HLA evidence where feasible. A peptide binding assay alone does not show intracellular processing. |
| Do T cells recognize the endogenous antigen? | Test relevant tumor targets, with wild-type or antigen-negative comparisons and HLA controls that fit the mechanism. |
| Does antigen breadth matter? | Compare defined single- and multiple-antigen conditions against heterogeneous target populations. |
| Does repeated APC exposure preserve function? | Compare scheduled antigen-matched exposure with suitable antigen and stimulation controls; measure recall and serial target cell function. |
| Which recognition mechanism contributes? | If a surface-targeted receptor is part of the study, use matched receptor conditions and separate surface target loss from peptide–HLA perturbation. |
Repeated stimulation can change differentiation and viability as well as function. A larger cell count or stronger early activation signal does not by itself establish a benefit in sustained tumor target recognition.
Evidence that would change the conclusion
An informative study reports the antigen configuration, HLA type, viable effector inputs and target cell state. Peptide-specific reagents and cytokine assays support recognition analysis, while matched tumor target assays address function. Serial challenge adds a different question: whether an initially observed response persists under continued antigen exposure.
APC, effector and target cell interventions should be separated whenever the mechanism requires it. If a compound changes killing, ask whether it affected priming, effector viability, target susceptibility or the assay signal itself. If a genetic modification changes the response, confirm the requested edit and compare an appropriately matched configuration.
CrossRelay supports the experimental systems and controls needed to test the underlying biology. KRAS configurations require project-specific evaluation of antigen, HLA context and function.
APC drug discovery study design